Joeri Kint was trained in Biotechnology and BioProcess Development (University in Wageningen, MSc 2006). During his career at Intervet International B.V. (2006-2009) and Merck Animal Health (2009-2016) he contributed to the development of several veterinary vaccines for viral diseases such as coronavirus and Influenza. His PhD work (2010-2015) focused on the development of cell lines for the production of these vaccines, which are produced using embryonated chicken eggs. In 2016 he moved to Biotype GmbH, Dresden, Germany. Here he set-up a novel department for contract development and production of In Vitro Diagnostic tests for oncology and infectious diseases. Since 2020 he is Head of Business Development at ExcellGene SA, Monthey, Switzerland where he is responsible for the entire business in EU and Asia-Pacific, including all COVID-related product-development programs.
Events/Masterclasses Dr. Joeri Kint is currently speaking at
No events currently available.
Are you interested in a custom-made event with this trainer?
Contact us to Request more information about your custom-made Corporate Learning program.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Joeri Kint was trained in Biotechnology and BioProcess Development (University in Wageningen, MSc 2006). During his career at Intervet International B.V. (2006-2009) and Merck Animal Health (2009-2016) he contributed to the development of several veterinary vaccines for viral diseases such as coronavirus and Influenza. His PhD work (2010-2015) focused on the development of cell lines for the production of these vaccines, which are produced using embryonated chicken eggs. In 2016 he moved to Biotype GmbH, Dresden, Germany. Here he set-up a novel department for contract development and production of In Vitro Diagnostic tests for oncology and infectious diseases. Since 2020 he is Head of Business Development at ExcellGene SA, Monthey, Switzerland where he is responsible for the entire business in EU and Asia-Pacific, including all COVID-related product-development programs.
